Ribavirin (Oral)

Monotherapy; Hemolytic Anemia; Teratogenicity

Monotherapy

• Ribavirin monotherapy is not effective for the treatment of chronic hepatitis C virus infection and should not be used alone for this indication 

Hemolytic Anemia

• The primary clinical toxicity of ribavirin is hemolytic anemia. The anemia associated with ribavirin therapy may result in worsening of cardiac disease that has led to fatal and nonfatal myocardial infarctions. Patients with a history of significant or unstable cardiac disease should not be treated with ribavirin

Teratogenicity, Contraindication in Pregnancy

• Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to ribavirin. In addition, ribavirin has a multiple dose half-life of 12 days, and it may persist in non-plasma compartments for as long as 6 months.
• Ribavirin therapy is contraindicated in women who are pregnant and in the male partners of women who are pregnant. Extreme care must be taken to avoid pregnancy during therapy and for 6 months after completion of therapy in both female patients and in female partners of male patients who are taking ribavirin therapy.
• At least two reliable forms of effective contraception must be utilized during treatment and during the 6-month posttreatment follow-up period.

Patient Counseling Information

• Copegus

• Rebetol

• Ribasphere

Medication Guides

Patient Medication Guide

Package Inserts

Ribavirin